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AbsTrACT
Objectives to quantify, among patients with axial 
spondyloarthritis (axSpA), the benefit on work outcomes 
associated with commencing biologic therapy. 
Methods the British Society for rheumatology 
Biologics register in Axial Spondyloarthritis 
(BSrBrAS) recruited patients meeting Assessment 
of SpondyloArthritis International Society criteria for 
axSpA naïve to biological therapy across 83 centres 
in Great Britain. Work outcomes (measured using the 
Work productivity and Activity Impairment Index) were 
compared between those starting biological therapy 
at the time of recruitment and those not. differences 
between treatment groups were adjusted using 
propensity score matching. results from BSrBr-AS 
were combined with other studies in a meta-analysis to 
calculate pooled estimates. 
results of the 577 participants in this analysis who 
were in employment, 27.9% were starting biological 
therapy at the time of recruitment. After propensity score 
adjustment, patients undergoing biological therapy, at 
12-month follow-up, experienced significantly greater 
improvements (relative to non-biological therapy) in 
presenteeism (−9.4%, 95% CI −15.3% to –3.5%), 
overall work impairment (−13.9%, 95% CI −21.1% 
to –6.7%) and overall activity impairment (−19.2%, 
95% CI −26.3% to –12.2%). there was no difference 
in absenteeism (−1.5%, 95% CI −8.0 to 4.9). despite 
these improvements, impact on work was still greater in 
the biological treated cohort at follow-up. In the meta-
analysis including 1109 subjects across observational 
studies and trials, treatment with biological therapy was 
associated with significantly greater improvements in 
presenteeism, work impairment and activity impairment, 
but there was no difference in absenteeism. 
Conclusions there is consistent evidence that 
treatment with biological therapy significantly improves 
work productivity and activity impairment in people with 
axSpA. However, there remain substantial unmet needs 
in relation to work.
InTrOduCTIOn
For working age adults, the ability to participate in 
working life is important from an economic stand-
point and for social and psychological health.1 
In a comprehensive review, Waddell and Burton2 
provided a clear evidence base for the positive 
impact work has on health and well-being. When 
these benefits are disrupted by unemployment, 
they found subsequent poorer mental and physical 
health, increased morbidity and higher consultation 
rates.2 People living with axial spondyloarthritis 
(axSpA) have identified the ability to stay at work as 
a priority.3 4
AxSpA can lead to significant functional limitations 
and reduced work productivity.4 5 Work disability 
affects up to 30% of patients with ankylosing spondy-
litis (AS).6–8 Compared with the general population, 
patients with AS report lower employment rates and 
more absenteeism.6 9 10 Boonen and van der Linden11 
reported that withdrawal from work was three times 
higher among patients with AS than observed in the 
general population, especially in those with physically 
demanding jobs.
Biological therapy leads to short-term and long-
term improvements in disease activity and health-re-
lated quality of life.12–14 However, evidence is 
equivocal on whether work outcomes are improved. 
In a systematic review, van der Burg et al15 demon-
strated significant improvements in presenteeism on 
biological therapy, but results were inconsistent on 
whether they improved absenteeism and allowed 
patients to stay in work.15
This study therefore aimed to determine, using a 
national disease register in Great Britain whether, 
among patients with axSpA, biological therapy was 
associated with better work outcomes in comparison 
with those not on such therapy, and to combine the 
results with other studies in a meta-analysis.
MeTHOds
The protocol of the British Society of Rheuma-
tology Biologics register in Axial Spondyloarthritis 
(BSRBR-AS) has previously been published.16 Briefly, 
patients were required to meet the Assessment of 
SpondyloArthritis International Society criteria for 
radiographic or non-radiographic axSpA at the time 
of recruitment and were required to be naïve to 
biological therapies. Eligible patients commencing on 
biological therapy were recruited to the ‘biological’ 
cohort, the remainder to the ‘non-biological’ cohort; 
this was based on clinical decision rather than study 
protocol. The biological cohort comprised patients 
commencing adalimumab, etanercept or certoli-
zumab pegol. Clinical data collected by site clinicians 
and research nurses at routine clinical appointments 
were entered into electronic case report forms at 
recruitment (baseline) and at 12-month follow-up. 
Patients were invited to self-complete a questionnaire 
at the same time-points, which included demographic 
 o
n
 2 N
ovem
ber 2018 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2018-213590 on 3 August 2018. Downloaded from
 
1579Shim J, et al. Ann Rheum Dis 2018;77:1578–1584. doi:10.1136/annrheumdis-2018-213590
Clinical and epidemiological research
information, smoking status, alcohol consumption, disease activity, 
AS-related measures and quality of life.
The impact of axSpA on work outcomes was measured using 
the Work Productivity and Activity Impairment: Specific Health 
Problem questionnaire.17 The questionnaire has been psycho-
metrically validated in AS18 and measures absenteeism (absence 
from paid work), presenteeism (at-work productivity loss), overall 
work impairment (combination of absenteeism and presenteeism, 
ie, reduced overall productivity) and overall activity impairment 
(reduced leisure activities), in relation to their disease. Higher 
scores, expressed as percentages, represent a worse state. Partic-
ipants who were in paid employment at baseline and completed 
both a baseline and 12-month follow-up questionnaire were 
eligible for this analysis. Analysis was conducted on the June 2017 
download of data. Appropriate National Health Service (NHS) 
Research and Development approvals were obtained for each site. 
All patients provided written informed consent.
bsrbr-As analysis
The principal outcomes of interest for this analysis were changes 
in self-reported absenteeism, presenteeism, overall work impair-
ment and overall activity impairment in the biological cohort in 
comparison with the non-biological cohort. In clinical practice, 
the decision to initiate biological therapy is strongly influenced by 
disease activity,19 and therefore, the biological and non-biological 
cohorts represent distinct clinical populations and direct compar-
ison would lead to confounding by indication. This was addressed 
by propensity matching. There is currently no strong consensus on 
the approach to variable selection for propensity score models,20 
but most relevant confounders were considered in our study, and 
where there were issues of collinearity, variables were omitted 
from the model based on the variance inflation factor. Propensity 
scores were developed based on age, gender, smoking status and 
disease duration in a logistic regression model. For each individual 
commencing biological therapy, nearest-neighbour propensity 
score was used to identify an individual for matching, not starting 
biological therapy, by accounting for covariates that predict treat-
ment assignment. Density distributions of the propensity scores of 
the two treatment groups were plotted and visually compared with 
ensure that the common support condition was met as per Cali-
endo and Kopeinig.21 The standardised differences and variance 
ratios for raw and matched observations for presenteeism, work 
impairment, activity impairment and absenteeism indicated that 
matching on the propensity score balanced the covariates: differ-
ences were close to zero and variance ratios close to one. After 
propensity score matching, the differences in work outcomes for 
the biological therapy and non-biological therapy groups were 
analysed. Independent-sample Student’s t-test was used for group 
comparisons of the changes in work outcomes. A sensitivity anal-
yses was conducted to explore the degree to which unmeasured 
confounding could alter study results, using the method proposed 
by Rosenbaum.22
Data analysis was performed using STATA V.14.0.
systematic review and meta-analysis
The conduct and reporting of this meta-analysis was guided by the 
Preferred Reporting Items for Systematic Reviews and Meta-Anal-
yses statement.23
Studies were eligible for inclusion based on the following 
criteria:
 ► Population: AxSpA by recognised criteria or clinical 
diagnosis.
 ► Study design: observational studies (prospective and retro-
spective cohort studies), randomised controlled trials (RCTs) 
and quasi-RCTs.
 ► Outcomes: outcomes reported included changes in work 
measures (eg, work status, WPAI, AS-Work Instability Scale 
(AS-WIS) and sick leave) for a biological treatment group 
versus a placebo/non-biological treatment group. Studies 
must have provided data in relation to this comparison or 
provided sufficient data to allow its calculation.
If more than one publication was identified based on the same 
cohort or population, a single report was selected based on the 
relevance of work measures reported and the largest number of 
subjects.
Studies were identified by searching electronic databases: Ovid 
MEDLINE, Embase, Evidence Based Medicine and Cochrane 
Library up to March 2018. Reference lists of articles were also 
screened for inclusion. The search strategy can be found in online 
supplementary appendix 1. Potentially eligible abstracts were 
screened by two reviewers, and any disagreements were resolved 
by discussion. Ten per cent of the articles excluded at full-text 
screening were independently reviewed by a third reviewer. One 
reviewer extracted relevant data from included studies, and a 
second reviewer cross-checked the extracted data. Disagreements 
were resolved by discussion among all three reviewers. Where it 
was considered that a study was potentially eligible but the way 
that the quantitative results were presented did not meet inclusion 
criteria, the corresponding author was contacted to determine 
whether the relevant data, to make the study eligible, could be 
provided.
For continuous outcome variables, the mean difference of 
change in work parameters, comparing biological and non-bio-
logical therapy groups, was calculated with 95% CIs. Heteroge-
neity was assessed using the χ2 statistic and quantified by I2; 0% 
≤ I2≤40% is considered to indicate minimal heterogeneity and 
I2 >40% moderate to high heterogeneity.24 In cases where there 
was no evidence of moderate to high heterogeneity, a fixed-ef-
fects model with inverse variance weighting was used to obtain 
an overall mean difference or effect estimate. If moderate to high 
heterogeneity was evident between studies, a random-effects 
model was adopted, and a sensitivity analysis was conducted by 
sequentially omitting individual studies to identify the influence of 
the study on the pooled outcome.
The meta-analysis was conducted using STATA V.14.0.
resulTs
Within the BSRBR-AS, 972 participants completed and returned 
both the baseline and 12-month follow-up questionnaire, of whom 
577 (59.4%) were employed at the time of recruitment. Of these, 
161 (27.9%) patients started biological therapy, while 416 did not, 
and these two cohorts form the study population for the current 
analysis (table 1). Persons starting biological therapy were younger 
(42.4 years vs 47.0 years), more likely to be smokers (21.3% vs 
11.0%) with greater disease activity (Bath Ankylosing Spondy-
litis Disease Activity Index 5.8 vs 3.3 and Ankylosing Spondylitis 
Disease Activity Scale 3.4 vs 2.3), poorer function (Bath Ankylosing 
Spondylitis Functional Index 5.4 vs 2.7) and Bath Ankylosing Spon-
dylitis Global Disease Status 6.7 vs 3.2) (table 1). Persons starting 
biological therapy also reported higher work impairments at the 
time of recruitment. They were more likely, during the previous 
week, to be absent from work (10.9% vs 2.8%), experience greater 
at-work productivity loss (41.0% vs 20.6%), overall productivity 
loss (42.3% vs 21.4%) and activity impairment (51.0% vs 24.0%) 
(table 1). Among those who had not reached normal retirement 
age at the time of follow-up, there was no significant difference in 
the proportion who were no longer in employment at follow-up 
(biological group 5.2% vs non-biological group 4.3%).
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Table 1 BSRBR-AS study: baseline characteristics of biological and 
non-biological cohorts
biological 
cohort
(n=161)
non-
biological 
cohort 
(n=416) difference* 95% CI
Age, mean years 42.4 47.0 −4.6 −6.6 to 2.5
Male, % 64.6 67.3 −2.7 −11.3 to 5.9
Disease duration, mean 
years 7.7 12.3 −4.6 −6.5 to 2.7
Current smokers, % 21.3 11.0 10.2 3.9 to 16.5
BASDAI 5.8 3.3 2.6 2.2 to 2.9
BASFI 5.4 2.7 2.7 2.3 to 3.2
BAS-G§ 6.7 3.2 3.4 3.0 to 3.9
CRP (mg/dL) 2.8 2.4 0.4 −0.8 to 1.6
ASDAS 3.4 2.3 1.1 0.9 to 1.3
Physical job, % 44.8 51.0 −6.2 −3.1 to 15.5
WPAI measures (in the last 7 days)
  Absenteeism, % 10.9 2.8 8.1 4.7 to 11.4
  Presenteeism, % 41.0 20.6 20.4 15.9 to 24.9
  Overall
  work impairment, % 42.3 21.4 20.9 16.2 to 25.7
  Overall activity 
impairment, % 51.0 24.0 27.0 22.5 to 31.4
*Difference=biological – non-biologic cohort.
ASDAS, Ankylosing Spondylitis Disease Activity Scale; BAS-FI, Bath Ankylosing Spondylitis 
Functional Index; BAS-G, Bath Ankylosing Spondylitis Global Disease Status; BASDAI, Bath 
Ankylosing Spondylitis Disease Activity Index; BSRBR-AS, British Society of Rheumatology 
Biologics register in Axial Spondyloarthritis; CRP, C reactive protein; WPAI, Work Productivity 
and Activity Impairment.
Figure 1 Crude changes in work outcomes after 1 year: BSRBR-AS 
study. BSRBR-AS, British Society of Rheumatology Biologics register in 
Axial Spondyloarthritis.
Table 2 BSRBR-AS study: changes in work outcomes between 
biological and non-biological cohort
WPAI measures (in 
the last 7 days)
biological 
cohort
non-biological 
cohort
Mean difference 
in change* 95% CI
Absenteeism, % −1.0 0.5 −1.5 −8.0 to 4.9
Presenteeism, % −11.9 −2.5 −9.4 −15.3 to − 3.5
Overall work 
impairment, %
−11.9 2.0 −13.9 −21.1 to − 6.7
Overall activity 
impairment, %
−17.6 1.6 −19.2 −26.3 to − 
12.2
+, deterioration; −, improvement.
*Difference=biological – non-biological cohort (adjusted for differences using propensity 
score matching).
WPAI, Work Productivity and Activity Impairment.
Persons receiving treatment with biological therapy experienced 
greater improvement in all work outcomes except absenteeism, 
at 12-month follow-up, compared with persons not receiving 
biological therapy (figure 1). These improvements remained 
after propensity score adjustments for differences between the 
cohorts. Patients on biological therapy demonstrated a significantly 
greater improvement in presenteeism (−9.4%, 95% CI −15.3% 
to –3.5%), overall work impairment (−13.9%, 95% CI −21.1% 
to –6.7%) and overall activity impairment (−19.2%, 95% CI 
−26.3% to –12.2%). These figures translate into a benefit of 
over half a day in terms of full productivity per week, 12 months 
after starting biological therapy. For absenteeism, there was only a 
small improvement noted in the biological cohort and no signifi-
cant difference compared with the non-biological cohort (−1.5%, 
95% CI −8.0% to 4.9%) (table 2). Nevertheless, despite the greater 
improvement in these work indices the impact on work was still 
greater in the biological-treated compared with the non-biologi-
cal-treated cohort at follow-up (presenteeism biological cohort 
– non-biological cohort adjusted for factors used in propensity 
matching: 11.5%, 95% CI 5.5% to 17.5%; overall work impair-
ment: 9.7%, 95% CI 3.6% to 15.9%; overall activity impairment: 
9.2%, 95% CI 2.5% to 16.1%).
The sensitivity analysis conducted showed that the results were 
insensitive to an unmeasured factor, which would increase the log 
odds of biological treatment by approximately 1.9 (presenteeism) 
and 2.0 (overall work impairment and activity impairment).
Meta-analysis
There were 686 publications identified, of which 547 were 
excluded because they were duplicates, conference abstracts, case 
reports or not relevant based on title and abstract screening. The 
remaining 139 publications were retrieved for full-text review. 
Of the six publications that were identified as potentially eligible, 
four were included in the meta-analysis; the remaining two were 
reporting studies already included25 26 (figure 2). Results of five 
studies (four identified in review and the current study) with a total 
of 1109 participants were therefore included in the meta-analysis. 
A summary of the characteristics of the studies included is shown 
in table 3. All of the studies (apart from BSRBR-AS) were RCTs. 
Three were multinational studies conducted in Europe, Asia and 
America,27–29 and the other was a study conducted within the UK30 
(table 3). Follow-up ranged from 3 months to 12 months, and 
the biological drugs used in the trials were infliximab, etanercept 
and secukinumab. Statistical heterogeneity tests showed minimal 
to moderate heterogeneity across studies and outcomes (I2=0%–
66%), and therefore, random effect models were used.
Three studies, with a total of 947 participants (346 biological 
therapy; 601 non-biological therapy), reported work measures 
using WPAI. There was a statistically significant difference (in 
favour of biological therapy groups) for improvement in presen-
teeism (mean difference (MD)=−5.35, 95% CI −10.68 to –0.02) 
and overall work impairment (MD=−11.20, 95% CI 
−16.31 to–6.10), that is, overall at-work productivity improved 
by 11% more among patients who received biological therapy 
compared with those on other therapies (figure 3). Furthermore, 
improvement in self-reported ability to perform daily activities was 
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Figure 2 PRISMA flow chart of study selection and inclusion (modified from Moher et al23). BSRBR-AS, British Society for Rheumatology Biologics 
Register in Axial Spondyloarthritis; OM, outcome measure; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PsA, 
psoriatic arthritis; RA, rheumatoid arthritis.
on average, 12% higher in patients treated with biological therapy 
(MD=−12.13, 95% CI −18.22 to –6.03) (figure 3). In contrast, 
there was little improvement in absenteeism in either treatment 
group; absolute change in biological therapy and non-biologic 
therapy groups across studies were −2.2% and −6.3%, respec-
tively, and the pooled change in absenteeism was similar in both 
groups (MD=0.84, 95% CI −3.54 to 5.22) (figure 3).
Only two studies measured work instability that included 163 
participants (80 biological; 83 non-biological therapy). On a stan-
dardised scale, treatment with biologic therapy was associated with 
a small improvement on the AS-WIS compared with the non-bio-
logical therapy group. However, this difference was not statistically 
significant (MD=−1.16, 95% CI −2.56 to 0.26) (online supple-
mentary appendix 2).
dIsCussIOn
Patients with axSpA recruited to a national disease register, who 
started biological therapy showed, on average, significantly 
greater improvements in work outcomes compared with those 
not commencing such therapy. Furthermore, pooled data across 
five cohorts with a total of 1109 patients with axSpA quanti-
fied that treatment with biological therapy leads to greater 
improvements in both work productivity (presenteeism (5%), 
overall work impairment (11%)) and activity impairment 
(12%)). There was however no benefit across all studies in rela-
tion to absenteeism.
The main strength of the BSRBR-AS study is the large sample 
size, national coverage and prospective study design. It provides a 
sample of patients with axSpA recruited from 83 outpatient clinics, 
including both specialist and non-specialist centres across Great 
Britain. Participants starting biological therapy have been shown 
to be similar in characteristics to patients with axSpA recruited to 
the trials of biological therapies.31 Although the effects on work 
outcomes could be estimated using an RCT, work outcomes are not 
routinely collected in such trials and they are rarely long enough 
for change to occur. As this was an observational study, propen-
sity score matching techniques were used to estimate the effect 
of treatment; this statistical technique addresses ‘confounding by 
indication’ due to treatment group differences. However, propen-
sity score analysis can only take into account measured factors 32. 
It is of note that measures of disease activity were not part of the 
propensity score. However, being highly discriminatory in terms 
of treatment assignment, this is to be expected, due to the lack of 
overlap between groups.
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Figure 3 Forest plot comparing changes in WPAI outcomes between patients in the biological and non-biological treatment groups. BSRBR-
AS, British Society of Rheumatology Biologics register in Axial Spondyloarthritis; WPAI, Work Productivity and Activity Impairment.
Sensitivity analyses suggested only a strong unmeasured 
confounder could explain the differences observed. Furthermore, it 
is of note that the results from the observational study (BSRBR-AS) 
were very similar to the results from the RCTs included in the 
meta-analysis (with little heterogeneity noted) suggesting that 
residual confounding has not been a major issue.
To our knowledge, this is the first meta-analysis to quantify 
the impact of biological therapy on work participation. One 
earlier systematic review included nine trials and examined the 
effect of biological treatment on three work outcomes: work 
status, absenteeism and presenteeism.15 It showed that presen-
teeism decreased by 17%–29% and absenteeism decreased by 
8.7–22.3 days over a period of 12 months after commence-
ment of biological therapy. However, these results were based 
on single group, pre-therapy and post-therapy analysis.15
Nevertheless, our review found few studies that investigated the 
impact of biological therapy on work-related outcomes and rela-
tively small sample sizes in the included trials. Although a substan-
tial improvement in presenteeism and overall work impairment 
was achieved in the biological cohort, our study shows a persisting 
gap relative to the non-biological cohort patients with axSpA. This 
suggests that pharmacological intervention alone is not enough to 
improve work participation. Overall, the BSRBR-AS study did not 
demonstrate improvements in absenteeism, and the meta-analysis 
did not demonstrate any significant differences in the improve-
ments on absenteeism between the biological and non-biological 
treatment groups. The group who experience presenteeism 
represent a large proportion of patients with axSpA, and while 
they are at high risk of absenteeism, this outcome is considerably 
less common.33 34 While we have shown that biological therapy 
improves presenteeism (relative to not receiving biological 
therapy), it does not necessarily mean therefore that this leads to 
an improvement in absenteeism. Our data are consistent with the 
hypothesis that absenteeism is a late stage in terms of work impair-
ment that is not reversed by biological therapy alone but likely 
also to be influenced by contextual factors. Zhang et al35 assessed 
the construct validity of the WPAI questionnaire among patients 
with rheumatoid arthritis and found absenteeism to correlate the 
least with health-related outcomes compared with other WPAI 
domains.35 Saidane et al36 also demonstrated that disease severity 
and disease activity were not associated with absenteeism among 
people with AS in a cohort study.36 We have shown in a previous 
analysis from BSRBR-AS that presenteeism predicts future absen-
teeism, which predicts future work loss. Taken together, these 
results emphasise that biological therapy may be less effective at 
improving work outcome when given late in the natural history 
of the condition.37 Cost-effectiveness analysis often consider 
costs from a payer’s perspective (in the UK, the NHS) rather than 
considering the wider societal costs (and benefits) associated with 
treatment. Although presenteeism is an important outcome, it 
would be interesting to extend existing cost-effectiveness estimates 
to take important work outcomes into account. However, these 
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data were not available and is therefore beyond the scope of the 
current study.
We conclude that there is consistent evidence, across different 
study designs, that treatment with biological therapy significantly 
and meaningfully improves work productivity and activity impair-
ment in people with axSpA. However, even with the improve-
ments observed with biological therapy, there is still a substantial 
impact on work. Future studies in axSpA should include assessment 
of work outcomes as standard, ensuring a greater evidence base 
around pharmacological and non-pharmacological approaches to 
improving work outcomes in patients with axSpA.
Correction notice this article has been corrected since it published online First. 
Figure 3 has been updated.
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